Robin Thompson
Overview
Explore the profile of Robin Thompson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
883
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bajaj S, Thompson R, Lambert B
Philos Trans A Math Phys Eng Sci
. 2025 Mar;
383(2292):20240357.
PMID: 40078145
During infectious disease outbreaks, delays in case reporting mean that the time series of cases is unreliable, particularly for those cases occurring most recently. This means that real-time estimates of...
2.
Ellis J, Mirzaian M, Sudduth E, Ashworth M, Thompson R, Johnson D, et al.
Subst Use Misuse
. 2025 Feb;
:1-13.
PMID: 39930779
Background: Substance use disorder (SUD) is a public health crisis in the United States (U.S.), with the associated mortality rates at an all-time high. Having access to Recovery Housing (RH),...
3.
Stranden I, Mantysaari E, Lidauer M, Thompson R, Gao H
Genet Sel Evol
. 2024 Nov;
56(1):73.
PMID: 39573996
Background: Methods for estimating variance components (VC) using restricted maximum likelihood (REML) typically require elements from the inverse of the coefficient matrix of the mixed model equations (MME). As genomic...
4.
Karr J, Malik-Sheriff R, Osborne J, Gonzalez-Parra G, Forgoston E, Bowness R, et al.
Front Syst Biol
. 2023 Mar;
2.
PMID: 36909847
During the COVID-19 pandemic, mathematical modeling of disease transmission has become a cornerstone of key state decisions. To advance the state-of-the-art host viral modeling to handle future pandemics, many scientists...
5.
Landeiro F, Morton J, Gustavsson A, Potashman M, Lecomte P, Belger M, et al.
Alzheimers Dement (N Y)
. 2022 Oct;
8(1):e12360.
PMID: 36313968
The successful development of an economic model for the evaluation of future Alzheimer's disease (AD) interventions is critical to accurately inform policy makers and payers. As our understanding of AD...
6.
Das S, Zuko A, Thompson R, Storkebaum E, Ignatova Z
Bio Protoc
. 2022 Mar;
12(4):e4335.
PMID: 35340290
Transfer RNAs (tRNAs) are highly abundant species and, along their biosynthetic and functional path, they establish interactions with a plethora of proteins. The high number of nucleobase modifications in tRNAs...
7.
Ashworth M, Thompson R, Fletcher E, Clancy G, Johnson D
J Addict Dis
. 2022 Feb;
40(4):538-541.
PMID: 35212253
Recovery housing provides substance-free living environments that use peer-support to empower individuals in recovery from substance use disorder. This study estimated the total revenue of the recovery housing industry from...
8.
Zuko A, Mallik M, Thompson R, Spaulding E, Wienand A, Been M, et al.
Science
. 2021 Sep;
373(6559):1161-1166.
PMID: 34516840
Heterozygous mutations in six transfer RNA (tRNA) synthetase genes cause Charcot-Marie-Tooth (CMT) peripheral neuropathy. CMT mutant tRNA synthetases inhibit protein synthesis by an unknown mechanism. We found that CMT mutant...
9.
Herring W, Gould I, Fillit H, Lindgren P, Forrestal F, Thompson R, et al.
Neurol Ther
. 2021 Aug;
10(2):919-940.
PMID: 34426940
Introduction: Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease that places a substantial burden on patients and caregivers. Aducanumab is the first AD therapy approved by the US...
10.
Gustavsson A, Pemberton-Ross P, Gomez Montero M, Hashim M, Thompson R
Expert Rev Pharmacoecon Outcomes Res
. 2020 Sep;
20(6):563-570.
PMID: 32951480
Introduction: Alzheimer's disease (AD) is a complex neurodegenerative disease, affecting millions of people worldwide and imposing heavy economic burdens to societies. Currently, only symptomatic treatments are available for patients, but...